TAK 165

Key Product Details

Product Description

TAK 165 is a potent, irreversible human epithelial growth factor receptor 2 (ErbB2) inhibitor (IC₅₀ = 6 nM) that displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC₅₀ = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.

Product Specifications for TAK 165

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for TAK 165

The following data is based on the product molecular weight 468.47.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.75 mM	2.85 mL	14.23 mL	28.46 mL
3.75 mM	0.57 mL	2.85 mL	5.69 mL
7.5 mM	0.28 mL	1.42 mL	2.85 mL
37.5 mM	0.06 mL	0.28 mL	0.57 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 3 publications citing the usage of this product.

• Nagasawa Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo. Int.J.Urol. 2006 PMID: 16771730
• Spector Small molecule HER-2 tyrosine kinase inhibitors. Breast Cancer Res.
• Sridhar Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003 PMID: 12850190

Product Documents for TAK 165